AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2021

Mar 3, 2021

30604_dirs_2021-03-03_4fe5267e-95e5-4978-a1a6-40789c1ea1c6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-03-01

Reporting Person: HOMCY CHARLES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	A	1521	$0.00	Acquired	1205288	Direct
2021-03-01	Common Stock	F	524	$71.91	Disposed	1204764	Direct

Footnotes

F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the grant and issuance of 1,521 vested shares of Common Stock.